文献速递甲状腺疾病

ATA超声分类联合细胞学亚分类可提升不确定甲状腺结节恶性风险评估

Combining the American Thyroid Association's Ultrasound Classification with Cytological Subcategorization Improves the Assessment of Malignancy Risk in Indeterminate Thyroid Nodules.
PubMed 文献 · Thyroid · 2020-12-10

该回顾性队列研究纳入巴西两个中心的238个不确定甲状腺结节,联合细胞学亚分类与ATA超声风险分类评估恶性风险。总体恶性频率39.5%,核异型(NA)和结构及核异型(ANA)与癌症独立相关,与ATA高风险超声特征联合时恶性风险可接近80%。

要点

  • NA和ANA与癌症独立相关,AA和OP无独立关联。
  • ATA高风险和中风险超声分类均与癌症独立相关。
  • NA或ANA联合ATA高风险超声时恶性风险>70%。

核心结论

  • 联合细胞学亚分类与ATA超声风险分类可改善不确定甲状腺结节的恶性风险评估。
  • NA和ANA与癌症风险独立相关,而AA和OP无独立关联。
  • 当NA和ATA高风险超声特征同时存在时,恶性风险可接近80%。

研究设计与样本

  • 回顾性队列研究,来自巴西两个中心,纳入238个结局确认的不确定甲状腺结节。
  • 根据ATA指南确定超声分类,并确定细胞学亚分类。

主要发现

  • 总体恶性频率为39.5%。
  • 细胞学亚分类中,NA的恶性风险为43.9%,ANA为43.5%,AA为29.4%,OP为9.4%。
  • NA或ANA联合ATA中风险超声模式时恶性风险分别为47.5%和56.7%;联合ATA高风险分类时恶性风险>70%。

关键数值与推荐

  • 细胞学亚分类包括:NA(与PTC相关的核异型但不足以分类为可疑恶性)、AA(无核异型的结构异型)、ANA(结构和核异型)、OP(无核异型的嗜酸细胞模式)、NANP(与PTC无关的核异型)。
  • NA进一步分为核大小和形状、核膜外观、染色质方面三个亚组。
  • 核膜相关NA与癌症的OR为11.5。

临床怎么用

  • 在决定分子检测、临床观察或诊断性手术前,建议联合细胞学亚分类和超声风险分类评估不确定甲状腺结节。
  • NA或ANA合并ATA中高风险超声特征时恶性风险较高,可能影响手术决策。
  • AA和OP与癌症风险无独立关联,可能适合更保守的管理。

局限性

  • 回顾性研究设计。
  • 样本来自两个巴西中心,可能存在选择偏倚。
  • 样本量为238个结节,部分亚组分析置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The risk of malignancy (RoM) of indeterminate thyroid nodules (ITNs) shows a high variability in interinstitutional cohorts. The RoM is partially associated with the cytological degree of atypia and the ultrasound (US) pattern. This study evaluated the cancer risk of ITNs by jointly considering the cytological subcategory and the American Thyroid Association (ATA)-based US risk classification. Methods: This study features a retrospective cohort from two Brazilian centers comprising 238 ITNs with confirmed outcomes. US classification, according to ATA-based guidelines, and cytological subcategorization were determined. The cytological subgroups were as follows: (1) nuclear atypia (NA) related to papillary thyroid carcinoma (PTC) but insufficient to categorize the cytology as suspicious for malignancy; (2) architectural atypia without NA (AA); (3) both architectural and nuclear atypia (ANA); (4) oncocytic pattern (OP) without NA; and (5) NA not related to PTC (NANP). NA was divided into three subgroups: nuclear size and shape, nuclear membrane appearance, and/or chromatin aspects. Results: The overall frequency of malignancy was 39.5%. Among the cytological subcategories, the highest RoM was related to the NA (43.9%) and to the ANA (43.5%), followed by AA (29.4%), and OP (9.4%). NA was positively and independently associated with cancer (odds ratio [OR]: 4.5; confidence interval [CI: 1.2-16.6]) as was the occurrence of ANA (OR 6.6 [CI 1.5-29.5]). AA and OP were not independently associated with cancer. Both ATA-based high- and intermediate-risk categories showed an independent association with cancer (OR 6.8 [CI 2.9-15.5] and OR: 2.6 [CI 1.1-5.8], respectively). ITNs with cytological findings of NA or ANA when combined with intermediate US patterns had RoM values of 47.5% and 56.7%, respectively. Both cytological subcategories, when combined with the ATA high-suspicion class reached an RoM >70%. The type of NA with the highest odds for cancer was related to the nuclear membrane (OR 11.5). Conclusions: The RoM of ITNs can reach almost 80% when both NA and ATA-based high-risk US features are present. The presence of such cytological features also increased the RoM in the ATA-based intermediate-risk US category. In addition, AA and OP were not independently related to higher cancer risk. These results strengthen the recommendations for combing cytological subcategorization and US risk classification in the workup for ITNs before the decision of a molecular testing, clinical observation, or diagnostic surgery.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Larcher de Almeida AM, Delfim RLC, Vidal APA, et al. Combining the American Thyroid Association's Ultrasound Classification with Cytological Subcategorization Improves the Assessment of Malignancy Risk in Indeterminate Thyroid Nodules. Thyroid. 2020. PMID: 33143569. doi:10.1089/thy.2019.0575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。